Despite the numerous limitations and unresolved issues surrounding blood GFAP level elevations, these levels remain broadly accepted as biomarkers reflecting neurodegenerative disease stages, not only specific to AD but also early amyloidosis, dementia or faster cognitive decline [4]. Here, GFAP is linked to neurodegenerative disease.